^
    Back
    Association details:
    Biomarker:KRT7 expression
    Cancer:Ampulla of Vater Carcinoma
    Drug:cisplatin (DNA synthesis inhibitor) +
    gemcitabine (DNA synthesis inhibitor) +
    albumin-bound paclitaxel (Bcl2 inhibitor, Tubulin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Cancer Med
    Title:

    Durable response for ampullary and duodenal adenocarcinoma with a nab-paclitaxel plus gemcitabine ± cisplatin combination

    Published date:
    07/01/2019
    Excerpt:
    Because the patient's tumor IHC profile (CK7 positivity)...therapy was switched to gemcitabine 400 mg/m2 and nab‐paclitaxel 125 mg/m2...On this regimen, the CEA levels rapidly decreased with disappearance of metastatic lung lesions and improvement in hoarseness....the patient is on maintenance chemotherapy with gemcitabine 300 mg/m2 and nab‐paclitaxel 125 mg/m2...and has maintained a stable, ongoing response for close to 3 years...
    DOI:
    10.1002/cam4.2181